News & Views
Process sets Pathway for market ready Graphene Solutions
Aug 10 2022
Scottish technology developer Integrated Graphene is investing up to £8 million to scale its 3D Graphene foam, Gii®, manufacturing process to meet surging global demand from the human diagnostics and energy markets.
Founded in 2016, Integrated Graphene has developed a commercially viable graphene manufacturing process that eliminates scale-up challenges associated with CVD graphene and graphene powder, through the development of a breakthrough process producing a pure 3D Graphene Foam onto a range of substances at ambient room temperature. The company also designs manufacturing processes for blue-chip companies to effectively bolt-on to existing lines and provides a dedicated team to supporting organisations that adapt graphene technologies for their products.
The company’s investment plan will focus on scaling-up the manufacturing of its enhanced electrodes and super capacitors which are currently being piloted by global blue-chips in human diagnostics point of care testing and smart label asset tracking applications.
As part of its strategic growth plans, the company intends to double its existing footprint in Stirling and treble its headcount to 100 over the next three years, hiring a significant number of market leading development and commercial experts in the UK, Europe and North America.
The company will also increase capital expenditure in its next generation pilot line to allow rapid market expansion of its core products including wearables, animal diagnostics, companion diagnostics and environmental diagnostics, with potential expansion markets including Drones, e-mobility, space, satellites and wearables.
The investment comes on the back of a significantly oversubscribed Series A + funding round for an undisclosed sum led by existing investors, Par Equity and Archangels.
Claus Marquordt, co-founder and CEO, Integrated Graphene said: “This investment marks a real tipping point for Integrated Graphene and the manufacturing of our unique 3D Graphene foam in its first two market-ready products. We are actively involved in projects with several global blue-chip companies to deliver high volumes of electrodes and super capacitors that address critical needs in accelerating point of care human diagnostics for a wide range of killer diseases and in enabling low-cost flexible and sustainable power systems for the booming IoT, Smart Label and Wearable tech markets. By investing now, we will be ready, this year, to produce millions of units per annum from a new facility in Stirling and to transfer the technology at scale to global partners in the future.”
More information online
In This Edition Chromatography Articles - Eco-Friendly RP-HPLC Mass Spectrometry & Spectroscopy Articles - Occurrence of PFAS in a variety of fish species from the Baltic Sea and freshw...
View all digital editions
Oct 04 2022 London, UK
Oct 09 2022 New Orleans, LA, USA
Oct 11 2022 Lisbon, Portugal
Oct 12 2022 Telford, UK
Oct 18 2022 Gothenburg, Sweden